186 related articles for article (PubMed ID: 35680625)
1. [Preparation of CD52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects].
Liu Y; Liu Y; Tang KJ; Chen ZQ; Mou JL; Xu YX; Xing HY; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):279-286. PubMed ID: 35680625
[No Abstract] [Full Text] [Related]
2. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
3. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
Min JT; Zhang L; Long CR; Fan HL; Li ZZ
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213
[No Abstract] [Full Text] [Related]
4. [An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
Chen GH; Huang HW; Wang Y; Liu HW; Xu LJ; Ma X; Xue SL; He XF; Wang Y; Gu B; Li CX; Qiu HY; Tang XW; Jin ZM; Miao M; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):148-152. PubMed ID: 29562451
[No Abstract] [Full Text] [Related]
5. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
6. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
7. [The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
Chen Y; Mo ZM; Qin DY; Guo FC; Liao XL; Hu M; Chen Q; Wang YS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):145-151. PubMed ID: 31106530
[TBL] [Abstract][Full Text] [Related]
8. [Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen].
He HZ; Xing YY; Zhang Y; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):229-234. PubMed ID: 35405781
[No Abstract] [Full Text] [Related]
9. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene.
Yuan W; Chen J; Cao Y; Yang L; Shen L; Bian Q; Bin S; Li P; Cao J; Fang H; Gu H; Li H
J Gene Med; 2018 Jul; 20(7-8):e3027. PubMed ID: 29851200
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
12. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
13. Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs.
Johnson AJ; Wei J; Rosser JM; Künkele A; Chang CA; Reid AN; Jensen MC
Cancer Immunol Res; 2021 Sep; 9(9):1047-1060. PubMed ID: 34244298
[TBL] [Abstract][Full Text] [Related]
14. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
15. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
16. [Research on the effect of PD-L1 overexpression on CLL-1 CAR-T anti-acute myeloid leukemia].
Lin GQ; Zhang YM; Kang LQ; Yu L; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):829-835. PubMed ID: 33190440
[No Abstract] [Full Text] [Related]
17. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
18. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
19. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
20. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
